Who
Matthew C. Busch
VP, Finance & CAO
Company insider
Files Form 4 as: VP, Finance & CAO, Amgen.
In numbers
- Trades disclosed
- 39
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $1.0M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 5 Nov 2023
- Last trade
- 7 Aug 2026
- Last filed
- 12 Aug 2026
Companies traded
Activity over time
1 Apr 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Aug 2026filed 12 Aug 2026 | AMGN AmgenBiotechnology | SEC FORM 4 Code A | —730 at $0.00 | filing |
| 7 Aug 2026filed 12 Aug 2026 | AMGN AmgenBiotechnology | SEC FORM 4 Code A | —730 at $0.00 | filing |
| 7 May 2026filed 11 May 2026 | AMGN AmgenBiotechnology | SEC FORM 4 Code F | $14K41 at $331.11 | filing |
| 7 May 2026filed 11 May 2026 | AMGN AmgenBiotechnology | SEC FORM 4 Code F | $14K41 at $331.11 | filing |
| 6 May 2026filed 7 May 2026 | AMGN AmgenBiotechnology | SEC FORM 4 Code F | $16K50 at $329.59 | filing |
| 6 May 2026filed 7 May 2026 | AMGN AmgenBiotechnology | SEC FORM 4 Code F | $16K50 at $329.59 | filing |
| 5 May 2026filed 7 May 2026 | AMGN AmgenBiotechnology | SEC FORM 4 Code A | —455 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | AMGN Amgenoption or derivative · Biotechnology | SEC FORM 4 Code A | $979K2,969 at $329.59 | filing |
| 5 May 2026filed 7 May 2026 | AMGN Amgenoption or derivative · Biotechnology | SEC FORM 4 Code A | $979K2,969 at $329.59 | filing |
| 5 May 2026filed 7 May 2026 | AMGN AmgenBiotechnology | SEC FORM 4 Code A | —455 at $0.00 | filing |
| 2 May 2026filed 5 May 2026 | AMGN AmgenBiotechnology | SEC FORM 4 Code F | $9,89530 at $329.82 | filing |
| 2 May 2026filed 5 May 2026 | AMGN AmgenBiotechnology | SEC FORM 4 Code F | $13K38 at $329.82 | filing |
| 2 May 2026filed 5 May 2026 | AMGN AmgenBiotechnology | SEC FORM 4 Code F | $9,89530 at $329.82 | filing |
| 2 May 2026filed 5 May 2026 | AMGN AmgenBiotechnology | SEC FORM 4 Code F | $13K38 at $329.82 | filing |
| 16 Mar 2026filed 18 Mar 2026 | AMGN AmgenBiotechnology | SEC FORM 4 Code F | $120K327 at $366.21 | filing |
| 16 Mar 2026filed 18 Mar 2026 | AMGN AmgenBiotechnology | SEC FORM 4 Code F | $120K327 at $366.21 | filing |
| 3 Mar 2026filed 5 Mar 2026 | AMGN AmgenBiotechnology | SEC FORM 4 Code A | —938 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | AMGN AmgenBiotechnology | SEC FORM 4 Code A | —938 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | AMGN AmgenBiotechnology | SEC FORM 4 Sold | $376K1,000 at $375.79 | filing |
| 19 Feb 2026filed 20 Feb 2026 | AMGN AmgenBiotechnology | SEC FORM 4 Sold | $376K1,000 at $375.79 | filing |
News
Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?AMGN · fool.com · 20 Oct 2026AMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026AMGN · prnewswire.com · 20 Oct 2026Amgen Has the Drugs and the Dividend. Now It Needs the GrowthAMGN · insidermonkey.com · 19 Oct 2026
0 headlines in the last 90 days name Matthew C. Busch; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.